Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS24-B044
- Development stage
- Preclinical
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
GS24-B044 is an inhaled small interfering RNA (siRNA) therapeutic candidate being developed by North America Genescience (GenSci) for the treatment of chronic obstructive pulmonary disease (COPD) and bronchiectasis. Developed using GenSci's proprietary Extrahepatic siRNA GPODS™ Platform, GS24-B044 is designed to target and downregulate Mucin-5AC (MUC5AC), a major gel-forming mucin that is overproduced in the airways of patients with chronic inflammatory lung diseases. By silencing MUC5AC expression directly in the lungs via inhalation, the therapy aims to reduce mucus hypersecretion, alleviate airway obstruction, and improve lung function. GS24-B044 is currently in the preclinical candidate (PCC) stage of development.
02
Targets
MUC5AC (Mucin-5AC)
Beyond the preview
Go deeper on GS24-B044.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS24-B044.